Australian Operations
   
Include All CSL Sites

News Archive

Media Enquiries

Sharon McHale
Sharon McHale
Head of Australia Public Affairs, 
Corporate Affairs and Communications
Mobile: +44 (0) 7810 757030
Email: Sharon.McHale@seqirus.com

27-10-2014
CSL to acquire Novartis’ influenza vaccine business
bioCSL to take on expanded role in global influenza vaccine industry

CSL Limited has today announced an agreement to acquire Novartis’ global influenza vaccine business for US$275 million, which will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. More.

21-07-2014
bioCSL partners with Immucor to distribute global market-leading transfusion testing technology
bioCSL today announced that it has commenced distribution of Immucor Corporation’s global market‐leading “Capture®” technology platform and reagents in Australia and New Zealand. Capture® is an advanced antibody detection technology used in the cross‐matching of blood used for transfusion. More.

11-06-2014
International Medical Journal Publishes bioCSL’s Fluvax® Investigation Findings
The findings of bioCSL’s multi-year investigation into the cause of the unexpected adverse events associated with its Fluvax® influenza vaccine in 2010 were today published in two separate papers in the peer-reviewed journal Vaccine. More.

30-04-2013
bioCSL goes back into influenza vaccine production for Australia
bioCSL announced today that it has recently restarted production of influenza vaccine for the Australian market in response to higher than expected demand this season. More.

 


 

Media Enquiries

Melanie Kerin
Senior Manager, Communications, 
Mobile: +61 (0) 417436329 
Email: Melanie.Kerin@seqirus.com

Share
LinkedIn Twitter Facebook Google+
© 2017 Seqirus